In the context of AD monitoring and therapeutic biomarker development, the incorporation of neurotrophic factors (NTFs, e.g., serum BDNF levels) into a dynamic monitoring framework incorporating serum biomarkers and tissue expression profiles is warranted. Here, BDNF is linked to Alzheimer disease.